Peixin Zhu joins Tevard Biosciences as the VP of R&D. He has about two decades of drug discovery and gene therapy development, experience ranging from developing A.I. HTS platforms for small molecules to advancing SMA Type I gene therapy through IND. He has a strong background across multiple scientific fields, including computational neuroscience, molecular biology, and gene therapies for CNS and liver indications including SMA, Dravet, Batten, DMD, Fabry, and Pompe diseases etc.. Prior to Tevard, Peixin was the VP of Discovery Research of LogicBio (NASDQ: LOGC, acquired by AstraZeneca). Prior to joining LogicBio, Peixin Zhu led multiple teams at the Novartis Institutes for Biomedical Research; Applied Genetic Technologies Corp. (NASDQ: AGTC; Acquired by Syncona); and Exegenesis Bio Inc. With leadership roles in R&D, he was responsible for establishing an in vivo A.I. HTS screening platform at Novartis, and for designing and bringing the 2nd generation SMA Type I gene therapy to early clinical stage at Exegenesis Bio. He and his team were also instrumental in several key partnerships including with the Stanley Center (Broad Institute), Florida State University.
